Back Pain News and Research

Latest Back Pain News and Research

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

Minimally invasive spine surgery poised for rapid growth

Minimally invasive techniques have become standard for many procedures, from the removal of the gallbladder to angioplasty, but the approach is now only beginning to be available to patients with spinal conditions. The surgical team at NewYork-Presbyterian Hospital/Columbia University Medical Center's Spine Center aims to bring the benefits of minimally invasive surgery for patients with intractable back pain, stenosis, spinal deformity, even spinal cancer.

4 Dec 2009

Legal immigrants still lack care in Massachusetts; Ohio hospitals brace for new fees

News outlets report on legal immigrants and the cost of health reform in Massachusetts, new hospital fees in Ohio, coverage shortfalls in Tennessee and registered nurse practitioners in Florida.

2 Dec 2009

RSNA: Dec. 2, 2009 briefing and presentations

A special press briefing will be held Wednesday, Dec. 2, at 10:45 a.m. CT (11:45 a.m. ET), featuring a panel of top experts who will discuss the recent U.S. Preventive Services Task Force (USPSTF) release of revised screening mammography guidelines. Many patients, breast cancer survivors, medical experts and government authorities dispute the guidelines as being without scientific evidence.

2 Dec 2009

J&JPRD submits an NDA for tapentadol ER tablets

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older.

2 Dec 2009

Childhood obesity can lead to spinal abnormalities

Being overweight as a child could lead to early degeneration in the spine, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2009

XenaCare Holdings becomes national sponsor of Arthritis Foundation

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.

27 Nov 2009

Exercise and education program reduces disability and improves physical function after back surgery

Patients who have undergone a single-level lumbar microdiskectomy for lumbar disk herniation experienced significant improvement in physical function following an intensive, progressive physical therapist guided exercise and education program, according to a research report published in the November issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association (APTA).

25 Nov 2009

Canadians with chronic neck and back pain now have access to top spinal care

Canadians suffering from chronic and severe neck and back pain now have access to the top spinal care available. Spinal heath expert, Dr. Ron Nusbaum, has launched Back Clinics of Canada, a state-of-the-art facility that focuses on educating patients on the importance of spinal health and offering cutting-edge care that can bring an end to back pain.

25 Nov 2009

Minimally invasive procedure relieves chronic back pain for retired school teacher

Carole Riggs, a retired teacher and school principal, points to her work during one Christmas vacation - bending, twisting and sitting on the floor to create games and teaching aids - as the primary culprit behind many years of back pain.

24 Nov 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

GOT YOUR BACK launches The Spinalis Chair

GOT YOUR BACK will be hosting an Open House at their retail location at 521 East Hector Street, Conshohocken, PA on December 12th from 1:00 p.m. - 4:00 p.m. Guests will include health and wellness professionals, chiropractors, massage therapists and those interested in alternative fitness and wellness throughout the tri-state area. Visitors will enjoy food, beverages, a free chair massage, and free on site diagnosis of the spine. This event is also open to the public and special discounts will be offered throughout the store exclusively for attendees of this event.

20 Nov 2009

Smartfish Technologies' patented ErgoMotion technology unveiled

Today, Smartfish Technologies launched its long-awaited ErgoMotion(TM) technology, the first ever design that combines the science of ergonomics with the technology of motion, resulting in a dramatic change and improvement in the way comfort is integrated into devices like mice and keyboards. Unveiled yesterday at Pepcom’s annual Wine, Dine and Demo event, ErgoMotion is the industry’s most advanced computer peripheral solution designed to relieve discomfort and repetitive stress injuries (RSI) related to extended computer usage.

20 Nov 2009

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).

19 Nov 2009

Tips for staying safe and healthy during Thanksgiving holiday

Visiting is a big part of the Thanksgiving holiday. But one place you don't want to stop by is the Emergency Department.

19 Nov 2009

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

St. Jude Medical, Inc. announced today that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.

18 Nov 2009

Majority of mothers personally manage their children's health this coming winter

Three out of four mothers with a child between the ages of two through 12 are extremely, very, or somewhat concerned about their child's health this coming winter, according to a survey conducted by Opinion Research Corporation and commissioned by Bionorica, an international company pioneering clinical research of natural remedies including Sinupret® for Kids, a product which supports healthy respiratory function in children (www.bionoricausa.com).

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the neuropathic pain drug market -- driven by the launches of several novel therapies -- will increase from $6 billion in 2008 to $9.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

16 Nov 2009